You have free access to this content

Cancer

Cover image for Cancer

15 June 2010

Volume 116, Issue 12

Pages 2847–3074

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Original Article
    7. Original Articles
    8. Correspondence
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Commentaries

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Original Article
    7. Original Articles
    8. Correspondence
    1. You have free access to this content
      CA 125 and the detection of recurrent ovarian cancer : A reasonably accurate biomarker for a difficult disease (pages 2850–2853)

      Robert C. Bast Jr

      Version of Record online: 7 APR 2010 | DOI: 10.1002/cncr.25203

      Rising cancer antigen 125 (CA125) levels have been used to detect recurrence of ovarian cancer. A recent study questions the value of this practice, but the clinical trial has significant limitations and discounts the value of early detection to permit treatment of recurrence with novel and conventional agents.

    2. You have free access to this content
      CA 125: Value or addiction? (pages 2854–2855)

      Patricia A. Goldman

      Version of Record online: 30 MAR 2010 | DOI: 10.1002/cncr.25185

      The author challenges a recent study indicating that there is no apparent benefit in routinely measuring cancer antigen 125 (CA 125) in the follow-up of women with ovarian cancer.

  3. Review Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Original Article
    7. Original Articles
    8. Correspondence
    1. You have free access to this content
      Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer (pages 2856–2867)

      Helena R. Chang

      Version of Record online: 1 APR 2010 | DOI: 10.1002/cncr.25120

      • original image

      Human epidermal growth factor receptor-2 (HER-2) positivity is a prognostic marker for frequent relapse and poor survival in 20% to 25% of patients with breast cancer. This article reviews the efficacy and safety data from studies of neoadjuvant therapy with the HER-2-targeted agent trastuzumab in early stage breast cancer.

    2. You have free access to this content
      Dose-dense temozolomide regimens : Antitumor activity, toxicity, and immunomodulatory effects (pages 2868–2877)

      Bart Neyns, Alicia Tosoni, Wen-Jen Hwu and David A. Reardon

      Version of Record online: 29 MAR 2010 | DOI: 10.1002/cncr.25035

      • original image

      This review summarizes efficacy and safety data from studies that investigated dose-dense temozolomide regimens in patients with recurrent glioma and advanced metastatic melanoma. The preclinical and clinical evidence of temozolomide-associated lymphodepletion that may enhance the host immune response to tumor-associated antigens and/or immunotherapy is also discussed.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Original Article
    7. Original Articles
    8. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment (pages 2878–2883)

      Alexandra S. Brown, Kelly K. Hunt, Jeannie Shen, Lei Huo, Gildy V. Babiera, Merrick I. Ross, Funda Meric-Bernstam, Barry W. Feig, Henry M. Kuerer, Judy C. Boughey, Christine D. Ching and Michael Z. Gilcrease

      Version of Record online: 6 APR 2010 | DOI: 10.1002/cncr.25066

      • original image

      In patients with confirmed lymph node-positive breast cancer at presentation who underwent successful sentinel lymph node (SLN) biopsy and axillary dissection after preoperative chemotherapy, the overall false-negative SLN rate was 22%, and the negative predictive value was 67%. Absence of treatment effect in SLNs after chemotherapy in patients with lymph node-positive disease at initial presentation has good sensitivity but low specificity for identifying a false-negative SLN.

    2. You have free access to this content
      Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer (pages 2884–2889)

      Laura S. Dominici, Viviana M. Negron Gonzalez, Aman U. Buzdar, Anthony Lucci, Elizabeth A. Mittendorf, Huong T. Le-Petross, Gildy V. Babiera, Funda Meric-Bernstam, Kelly K. Hunt and Henry M. Kuerer

      Version of Record online: 6 APR 2010 | DOI: 10.1002/cncr.25152

      • original image
      • original image

      The administration of trastuzumab concurrently with chemotherapy in patients with fine-needle aspiration biopsy-proven axillary lymph node metastases reportedly resulted in the eradication of lymph node metastases in 74% of patients. Elimination of lymph node disease correlated with significantly improved disease-free survival.

    3. You have free access to this content
      Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy (pages 2890–2901)

      Ho-Young Yhim, Sae-Won Han, Do-Youn Oh, Wonshik Han, Seock-Ah Im, Tae-You Kim, Young Tae Kim, Dong-Young Noh, Eui Kyu Chie, Sung Whan Ha, In Ae Park and Yung-Jue Bang

      Version of Record online: 1 APR 2010 | DOI: 10.1002/cncr.25054

      • original image
      • original image
      • original image
      • original image

      In patients with a limited number of isolated lung metastases from breast cancer, disease-free interval and biologic subtypes of the tumor were firm, independent, prognostic factors for progression-free survival and overall survival. Pulmonary metastasectomy can be a reasonable treatment option for patients with a small volume of metastases.

    4. Endocrine Disease
      You have free access to this content
      The 5-HT2B receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment (pages 2902–2912)

      Bernhard Svejda, Mark Kidd, Francesco Giovinazzo, Karim Eltawil, Bjorn I Gustafsson, Roswitha Pfragner and Irvin M. Modlin

      Version of Record online: 6 APR 2010 | DOI: 10.1002/cncr.25049

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      To elucidate the inter-relation of 5-HT to neuroendocrine tumor microenvironment, growth regulation, and fibrosis, we developed a neuroendocrine tumor (NET) fibroblast coculture system and evaluated the antiproliferative, antifibrotic, and signaling mechanisms of a novel specific 5-HT2B receptor antagonist. Our results demonstrate that targeting the 5-HT2B receptor may be an effective antiproliferative and antifibrotic strategy for small intestinal NETs because it inhibits tumor microenvironment fibroblasts as well as NET cell proliferation and profibrotic growth factor secretion.

    5. Gastrointestinal Disease
      You have free access to this content
      Serum sE-selectin levels and carcinoembryonic antigen mRNA-expressing cells in peripheral blood as prognostic factors in colorectal cancer patients (pages 2913–2921)

      Patrizia Ferroni, Mario Roselli, Antonella Spila, Roberta D'Alessandro, Ilaria Portarena, Sabrina Mariotti, Raffaele Palmirotta, Oreste Buonomo, Giuseppe Petrella and Fiorella Guadagni

      Version of Record online: 24 MAR 2010 | DOI: 10.1002/cncr.25094

      • original image
      • original image
      • original image
      • original image

      The authors demonstrated that analysis of presurgical serum sE-selectin levels, either alone or in combination with detection of carcinoembryonic antigen (CEA) mRNA-expressing cells in peripheral blood, might act as a prognostic factor in terms of recurrence-free survival in colorectal cancer (CRC) patients. This finding, together with the independent value of both CEA mRNA positivity and tumor necrosis factor-α (TNF-α) levels in predicting sE-selectin levels in CRC patients, suggests that CEA is capable of triggering a molecular cascade beginning with increased local production of TNF-α and culminating in up-regulated expression of E-selectin on the endothelium, as recently suggested in experimental models.

    6. You have free access to this content
      Association of local capacity for endoscopy with individual use of colorectal cancer screening and stage at diagnosis (pages 2922–2931)

      Jennifer S. Haas, Phyllis Brawarsky, Aarthi Iyer, Garrett M. Fitzmaurice, Bridget A. Neville, Craig Earle and Celia Patricia Kaplan

      Version of Record online: 12 APR 2010 | DOI: 10.1002/cncr.25093

      Increasing the use of colorectal cancer (CRC) screening may require interventions to improve capacity for endoscopy in some areas. The characteristics of the area where an individual resides may in part mediate disparities in CRC screening use for both African Americans and Hispanics, and disparities in cancer stage for Hispanics.

    7. You have free access to this content
      Adjuvant therapy and survival after resection of pancreatic adenocarcinoma : A population-based analysis (pages 2932–2940)

      Skye C. Mayo, Donald F. Austin, Brett C. Sheppard, Motomi Mori, Donald K. Shipley and Kevin G. Billingsley

      Version of Record online: 24 MAR 2010 | DOI: 10.1002/cncr.25082

      • original image
      • original image

      In patients with resected pancreatic cancer, multifactorial analysis of survival demonstrated an association between the receipt of adjuvant therapy and extended postoperative survival. These data underscore the importance of adjuvant therapy in resected pancreatic adenocarcinoma and the need for ongoing clinical trials to refine the efficacy and timing of adjuvant therapy in this disease.

    8. You have free access to this content
      Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer (pages 2941–2953)

      Jennifer M. Yeh, Chin Hur, Karen M. Kuntz, Majid Ezzati and Sue J. Goldie

      Version of Record online: 29 MAR 2010 | DOI: 10.1002/cncr.25030

      • original image
      • original image
      • original image
      • original image

      The current results indicated that endoscopic treatment and surveillance of advanced precancerous gastric lesions has the potential to significantly reduce the mortality and morbidity associated with gastric cancer and has a cost-effectiveness ratio that would be considered attractive in the United States. Surveillance of less advanced gastric lesions also may reduce cancer risk but did not appear to be cost-effective, except possibly for immigrants from high-risk countries.

    9. Genitourinary Disease
      You have free access to this content
      High-risk patients with hematuria are not evaluated according to guideline recommendations (pages 2954–2959)

      Keren Elias, Robert S. Svatek, Samir Gupta, Richard Ho and Yair Lotan

      Version of Record online: 30 MAR 2010 | DOI: 10.1002/cncr.25048

      • original image

      Subjects at high risk for bladder cancer based on ≥10 years of smoking or environmental exposure with microscopic hematuria are rarely evaluated thoroughly and only 12.8% were referred for urologic evaluation. Further studies are needed to evaluate both the utilization and effectiveness of guidelines for hematuria.

    10. You have free access to this content
      Extensive inguinal lymphadenectomy improves overall 5-year survival in penile cancer patients : Results from the Surveillance, Epidemiology, and End Results program (pages 2960–2966)

      Timothy V. Johnson, Wayland Hsiao, Keith A. Delman, Ashesh B. Jani, Otis W. Brawley and Viraj A. Master

      Version of Record online: 29 MAR 2010 | DOI: 10.1002/cncr.25091

      • original image
      • original image

      A significant number of penile cancer patients at risk for metastases have not received potentially curative inguinal lymphadenectomy, despite guidelines. Of patients receiving lymph node dissections, those involving examination of ≥8 lymph nodes experienced significantly higher overall 5-year survival.

  5. Original Article

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Original Article
    7. Original Articles
    8. Correspondence
    1. Disease Site

      Genitourinary Disease
      You have free access to this content
      Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy (pages 2967–2973)

      Brian R. Lane, Armine K. Smith, Benjamin T. Larson, Michael C. Gong, Steven C. Campbell, Derek Raghavan, Robert Dreicer, Donna E. Hansel and Andrew J. Stephenson

      Version of Record online: 1 APR 2010 | DOI: 10.1002/cncr.25043

      • original image

      Before nephroureterectomy, only 48% of patients were eligible to receive cisplatin-based combination chemotherapy (eGFR >60 mL/min/1.73m2) and this proportion decreased to 22% postoperatively. Multimodal treatment strategies for UTUC should focus on neoadjuvant chemotherapy, based on level I evidence for bladder cancer and a 50% reduction in renal function following nephrectomy, which creates additional risk from cisplatin use after surgery.

  6. Original Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Original Article
    7. Original Articles
    8. Correspondence
    1. Disease Site

      Head and Neck Disease
      You have free access to this content
      Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma (pages 2974–2983)

      Libero Santarpia, Jeffrey N. Myers, Steven I. Sherman, Francesco Trimarchi, Gary L. Clayman and Adel K. El-Naggar

      Version of Record online: 30 MAR 2010 | DOI: 10.1002/cncr.25061

      • original image
      • original image
      • original image
      • original image

      Rearranged during transfection (ret) proto-oncogene/papillary thyroid carcinoma (RET-PTC) and paired box-8 (PAX8)/peroxisome proliferator-activated receptor γ (PPARγ) fusion protein (PAX8-PPARγ) rearrangements and mutations of the neuroblastoma RAS viral oncogene homolog N-RAS at codon 61 are the most common genetic alterations in follicular variant papillary thyroid carcinoma. Activation of the mitogen-activated protein kinase pathway is a frequent event in the follicular variant of papillary thyroid carcinoma (FVPTC), but the phosphoinositide 3-kinase signaling pathway could be coactivated in RET-PTC tumors. These findings might have important therapeutic implication in patients with FVPTC.

    2. You have free access to this content
      A single nucleotide polymorphism in the alcohol dehydrogenase 7 gene (alanine to glycine substitution at amino acid 92) is associated with the risk of squamous cell carcinoma of the head and neck (pages 2984–2992)

      Sheng Wei, Zhensheng Liu, Hui Zhao, Jiangong Niu, Li-E Wang, Adel K. El-Naggar, Erich M. Sturgis and Qingyi Wei

      Version of Record online: 24 MAR 2010 | DOI: 10.1002/cncr.25058

      The authors conducted a hospital-based study of patients with squamous cell carcinoma of the head and neck (SCCHN) to verify the recently reported association between a potentially functional single nucleotide polymorphism (SNP) of the alcohol dehydrogenase 7 gene (ADH7). An SNP in ADH7, an alanine-to-glycine substitution at amino acid 92, was associated with the risk of SCCHN in non-Hispanic white populations.

    3. Hematologic Malignancies
      You have free access to this content
      Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma : A population-based study (pages 2993–3000)

      Susan M. Geyer, Lindsay M. Morton, Thomas M. Habermann, Cristine Allmer, Scott Davis, Wendy Cozen, Richard K. Severson, Charles F. Lynch, Sophia S. Wang, Matthew J. Maurer, Patricia Hartge and James R. Cerhan

      Version of Record online: 30 MAR 2010 | DOI: 10.1002/cncr.25114

      This study recruited 1286 newly diagnosed patients with non-Hodgkin lymphoma through population-based cancer registries from 1998 to 2000. Those patients who smoked, consumed alcohol, or were obese before diagnosis had a poorer overall and lymphoma-specific survival after adjustment for clinical and demographic factors.

    4. You have free access to this content
      Gemtuzumab ozogamicin as first-line treatment in patients aged 70 years or older with acute myeloid leukemia (pages 3001–3005)

      Wassim McHayleh, Kenneth Foon, Robert Redner, Rajesh Sehgal, Anastasios Raptis, Mounzer Agha, The Minh Luong, James J. Schlesselman and Michael Boyiadzis

      Version of Record online: 30 MAR 2010 | DOI: 10.1002/cncr.25078

      • original image
      • original image

      Elderly patients with acute myeloid leukemia were unable to withstand the rigors of intensive induction chemotherapy and its attendant complications. Gemtuzumab ozogamicin has demonstrated activity in recurrent acute myeloid leukemia. Gemtuzumab ozogamicin should be considered as a first-line treatment option in older patients with acute myeloid leukemia with intermediate-risk cytogenetics who are unable to tolerate high-dose induction chemotherapy.

    5. Hepatobiliary Disease
      You have free access to this content
      Selecting an optimal staging system for hepatocellular carcinoma : Comparison of 5 currently used prognostic models (pages 3006–3014)

      Chia-Yang Hsu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Pui-Ching Lee, Che-Chuan Loong, Jen-Huey Chiang, Teh-Ia Huo and Shou-Dong Lee

      Version of Record online: 30 MAR 2010 | DOI: 10.1002/cncr.25044

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Selecting an appropriate staging system is crucial to predict the outcome of patients with hepatocellular carcinoma (HCC). We found that the Cancer of the Liver Italian Program (CLIP) system is the best long-term prognostic model for HCC in a cohort of patients with early to advanced stage of HCC independent of treatment strategy.

    6. Lung Disease
      You have free access to this content
      Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance (pages 3015–3024)

      Junko Kikuchi, Ichiro Kinoshita, Yasushi Shimizu, Eiki Kikuchi, Jun Konishi, Satoshi Oizumi, Kichizo Kaga, Yoshihiro Matsuno, Masaharu Nishimura and Hirotoshi Dosaka-Akita

      Version of Record online: 30 MAR 2010 | DOI: 10.1002/cncr.25128

      • original image
      • original image

      The current study demonstrated that normal bronchial epithelia has abundant expression of the Bmi1 polycomb ring finger oncogene Bmi1 and sporadic expression of enhancer of zeste homolog 2 (EZH2) and that high expression of EZH2, but not Bmi1, in tumor cells is a prognostic factor associated with tumor histology and aggressiveness. These findings suggested that Bmi1 and EZH2 play distinctive roles in nonsmall cell lung cancers (NSCLCs) and that EZH2 expression may provide a novel prognostic marker for NSCLCs.

    7. You have free access to this content
      Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy (pages 3025–3033)

      Seung Tae Kim, Jeeyun Lee, Jeong-hoon Kim, Young-Woong Won, Jong-Mu Sun, Jina Yun, Yeon Hee Park, Jin Seok Ahn, Keunchil Park and Myung-Ju Ahn

      Version of Record online: 6 APR 2010 | DOI: 10.1002/cncr.25130

      • original image

      Gefitinib and erlotinib appear to have similar antitumor activity in terms of response rate and overall survival in pretreated patients with metastatic or recurrent nonsmall cell lung cancer.

    8. Discipline

      Outcomes Research
      You have free access to this content
      Physical performance limitations among adult survivors of childhood brain tumors (pages 3034–3044)

      Kirsten K. Ness, E. Brannon Morris, Vikki G. Nolan, Carrie R. Howell, Laura S. Gilchrist, Marilyn Stovall, Cheryl L. Cox, James L. Klosky, Amar Gajjar and Joseph P. Neglia

      Version of Record online: 1 APR 2010 | DOI: 10.1002/cncr.25051

      • original image
      • original image
      • original image

      The objective of this study was to evaluate muscle strength, fitness, physical performance, and task participation among adult survivors of childhood brain tumors. Muscle strength and fitness values among brain tumor survivors were similar to those among individuals aged ≥60 years and were associated with physical performance limitations.

    9. Pediatric Oncology
      You have free access to this content
      Childhood cancer in relation to parental race and ethnicity : A 5-state pooled analysis (pages 3045–3053)

      Eric J. Chow, Susan E. Puumala, Beth A. Mueller, Susan E. Carozza, Erin E. Fox, Scott Horel, Kimberly J. Johnson, Colleen C. McLaughlin, Peggy Reynolds, Julie Von Behren and Logan G. Spector

      Version of Record online: 7 APR 2010 | DOI: 10.1002/cncr.25099

      • original image

      There is significant variability in childhood cancer risk across racial/ethnic groups. However, mixed ancestry children appear to have risks more similar to racial/ethnic minority children than the white majority group.

    10. You have free access to this content
      Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma (pages 3054–3060)

      Brian H. Kushner, Kim Kramer, Shakeel Modak, Li-Xuan Qin and Nai-Kong V. Cheung

      Version of Record online: 1 APR 2010 | DOI: 10.1002/cncr.25232

      Among 126 patients treated with high-dose cyclophosphamide, topotecan, and vincristine for chemoresistant neuroblastoma, responses were significantly less likely to occur in children with disease that was persistent or progressing while receiving treatment than in those who were newly recurrent off treatment, as well as in adolescents/adults. These findings are broadly applicable and should be considered when designing, and interpreting the results of, phase 2 studies.

    11. Symptom Control and Palliative Care
      You have free access to this content
      Characteristics of patients who refuse do-not-resuscitate orders upon admission to an acute palliative care unit in a comprehensive cancer center (pages 3061–3070)

      Henrique A. Parsons, Maxine J. de la Cruz, Donna S. Zhukovsky, David Hui, Marvin O. Delgado-Guay, Adenike E. Akitoye, Badi El Osta, Lynn Palmer, Shana L. Palla and Eduardo Bruera

      Version of Record online: 1 APR 2010 | DOI: 10.1002/cncr.25045

      • original image
      • original image

      Refusal of Do-Not-Resuscitate orders was found to be low (4%). It was associated with higher pain and nausea, absence of advance directives, and longer survival.

  7. Correspondence

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Original Article
    7. Original Articles
    8. Correspondence
    1. You have free access to this content
      The role of postoperative radiotherapy for the treatment of gangliogliomas (page 3071)

      Miguel Gelebert-Gonzalez and Ramon Serramito-Garcia

      Version of Record online: 7 APR 2010 | DOI: 10.1002/cncr.25272

    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content

SEARCH

SEARCH BY CITATION